BMC Cancer (Jul 2023)

S100A family is a group of immune markers associated with poor prognosis and immune cell infiltration in hepatocellular carcinoma

  • Yuchen Qi,
  • Yujing Zhang,
  • Jianwen Li,
  • Mengting Cai,
  • Bo Zhang,
  • Zhangtao Yu,
  • Yuhang Li,
  • Junkai Huang,
  • Xu Chen,
  • Yinghui Song,
  • Sulai Liu

DOI
https://doi.org/10.1186/s12885-023-11127-3
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 17

Abstract

Read online

Abstract Background Hepatocellular carcinoma (HCC) is one of the most common human cancers with poor prognosis in the world. HCC has become the second leading cause of cancer-related death in China. It is urgent to identify novel biomarker and valid target to effectively diagnose, treat or predict the prognosis of HCC. It has been reported that S100A family is closely related to cell proliferation and migration of different cancers. However, the values of S100As in HCC remain to be further analyzed. Methods We investigated the transcriptional and translational expression of S100As, as well as the value of this family in HCC patients from the various databases. Results S100A10 was most relevant to HCC. Conclusions The results from HCC patients’ tissues and different cells also confirmed the role of S100A10 in HCC. Furthermore, we proved that S100A10 could influenced the cell proliferation of HCC cells via ANXA2/Akt/mTOR pathway. However, it would appear that the relationship between S100A10 and HCC is complex and requires more research.

Keywords